Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: The combination of ANT2 shRNA and hNIS radioiodine gene therapy increases CTL cytotoxic activity through the phenotypic modulation of cancer cells: combination treatment with ANT2 shRNA and I-131

Figure 5

In vivo visualization of the antitumor effects of ANT2 shRNA and hNIS radioiodine combination therapy. (A) The in vivo tumor treatment schedule is shown. (B) The tumor growth inhibition effects were monitored in vivo using bioluminescent imaging. (C) The tumor growth quantification is shown. CT26/NF cells were transplanted s.c. into the right thighs of immunocompetent Balb/c mice. Fourteen days later, tumor growth was measured using bioluminescence. Then, the tumor-bearing mice were treated with scramble (supplemented with Lipofectamine 2000), ANT2 shRNA (supplemented with Lipofectamine 2000), I-131, and combination therapy according to a designated schedule through an intravenous or intratumoral route. The data shown are the mean of triplicate experiments; the bars represent the mean±SD (n = 7 mice/group).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us